C4 Therapeutics, Inc. CCCC
NasdaqSmall CapHealthcare
13F Pro quality score
Rank #2,482 of 2,925
Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.
Reading the latest SEC filing…
13F Pro quality score
Rank #2,482 of 2,925
Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.
Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.
Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.
C4 Therapeutics, Inc. (CCCC) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CCCC at 29.8/100 on a composite quality score built from its SEC filings, placing it at rank #2,482 of 2,925 stocks — the bottom half of the AI-ranked universe. CCCC scores in the top quartile across institutional flow (97.1), revenue growth (79.7). Areas of concern include free cash flow (4.3) and profitability (4.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 4.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), C4 Therapeutics, Inc. reports quarterly revenue of $6.6M, net income of $-23.6M, free cash flow of $-1.6M. CCCC trades on the Nasdaq exchange and files with the SEC under CIK 1662579. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CCCC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for C4 Therapeutics, Inc. directly from SEC EDGAR.